Published in final edited form as:

Front Biosci (Elite Ed). ; 4: 2617–2637.

Age related cardiovascular dysfunction and effects of physical activity

Fabio Galetta¹, Angelo Carpi², Nader Abraham³, Emanuele Guidotti¹, Matteo A. Russo⁴, Marcello Camici¹, Alessandro Antonelli¹, Ferdinando Franzoni¹, and Gino Santoro¹

¹Department of Internal Medicine, University of Pisa, Pisa, Italy

²Department of Reproduction and Ageing, University of Pisa, Pisa, Italy

³Department of Physiology and Pharmacology, University of Toledo, USA

⁴Department of Cellular and Molecular Pathology, IRCCS San Raffaele Pisana, Rome, Italy

Abstract

The aim of the present article is to review the principal pathogenetic pathways of age-related cardiovascular changes and the positive effects of physical activity on these changes as well as on related cardiovascular dysfunction. The ageing mechanisms reviewed have been grouped into reduced tolerance of oxidative stress, loss of cardiac stem cells, cardiovascular remodeling and impairment of neurovegetative control. New pathogenetic conditions and their tests are described (sirtuins, telomere length, heart rate variability). Age related cardiovascular changes predispose the individual to arterial hypertension, heart failure and arrhythmia. A broad spectrum of tests are available to identify and monitor the emerging cardiovascular dysfunction. Physical activity influences all age related cardiovascular mechanisms, improves cardiovascular function and even, at moderate intensity can reduce mortality and heart attack risk. It is likely that the translation of laboratory studies to humans will improve understanding and stimulate the use of physical activity to benefit cardiovascular patients.

Keywords

Cardiovascular aging; Physical activity; Review

2. INTRODUCTION

Age-related cardiovascular changes or dysfunctions are associated with alterations leading to reduced cardiac performance, arrhythmias and arterial blood pressure increase. Usually, these changes while they can contribute to cardiac failure do not manifest relevant clinical symptoms, if concomitant coronary heart disease (CHD), valvular disease, cardiomyopathy or severe arterial hypertension are present.

Sedentary lifestyle is responsible for a large portion of age-related changes in the cardiovascular system. Physical activity per se can produce contrasting effects e.g. severe symptoms, such as dyspnoea and arrhythmias, in the case of severe cardiovascular disease (CVD), while it can have a preventive/therapeutical effect in age-related cardiac dysfunction (1).

The aim of the present review is to examine the principal pathogenetic pathways of age-related cardiovascular changes and the positive effects of physical activity, on these changes as well as on related cardiovascular dysfunction.

3. CARDIAC AGEING

3.1. Molecular and cellular mechanisms of aged cardiomyocytes

Ageing is an independent risk factor in reduced cardiac function and of heart disease. The myocardium can undergo a number of age-related degenerative processes in which cells die and surviving cardiomyocytes become hypertrophic (2). Although recent reports suggest that cardiomyocytes can regenerate, differentiating from stem cells (2–4), it is unclear whether these cells can fully integrate in the adult myocardium and restore the lost function. The structural and functional age-related alterations and the loss of cardiomyocytes directly affect cardiac function, leading to left ventricular hypertrophy and reduction in ejection fraction, heart rate and cardiac index (5). Aged cardiomyocytes exhibit a number of molecular, morphological and functional changes when compared to young cardiomyocytes.

3.2. Oxidative stress

Aged cardiomyocytes have a reduced resistance to oxidative stress, frequently related to the decreased expression of anti-oxidative systems and heat shock proteins. Cytochrome C oxidase is barely detectable in aged cardiomyocytes and this is an important reason of reduced mitochondrial respiratory activity and ATP synthesis (6). Aged cardiomyocytes display a reduction in contractility/relaxation ability, frequently due to alterations of the cytosolic energy-requiring Ca^{++} homeostasis and to reduced cell energy charge (7).

An altered balance between an overproduction of free radicals and a decreased ability of the cell to detoxify these highly reactive molecular species results in oxidative stress, a set of changes constantly present in ageing and that cardiomyocytes share with a large number of other cells. Oxygen-derived species with unpaired electrons include superoxide anion, hydrogen peroxide, hydroxyl radicals and peroxynitrites. All are highly reactive with biological molecules, damaging proteins, lipids, sugars and, especially, nucleic acids (8). The overproduction of radicals can be caused by exogenous agents such as smoking, polluting substances, radiation, drugs and foods, and/or by endogenous condition such as chronic inflammation (activated leukocytes), inefficiency of ATP synthesis (altered respiratory chain, overexpression of uncoupling proteins, mutations in mitochondrial DNA), and other metabolic alterations (diabetes, uricemia, prolonged and strenuous exercise, etc). On the other hand, a substantial contribution to the net increase in free radical concentration may be derived from the loss of detoxifying and scavenging activity of various molecules and systems including glutathione, superoxydismutases, bilirubin, thioredoxin and

vitamin E. The resistance to oxidative stress is coordinated by FOXO3, the master transcription factor controlling the expression of GADD45 (DNA repair), Mn-SOD and Cu/Zn-SOD (free radical detoxifying activity), HSP70 and HSP32 (protein protection and recovery), the inducible form of heme oxygenase (HO1, producing cytosolic bilirubin), iNOS and a large number of other genes with scavenging and cardioprotective activity (9,10).

Figure 1 describes the protective role of SODs in cardiovascular diseases. FOXO3 can be activated by the redox state of the cytosol. In humans sirtuins are associated with longevity and appear to be involved in the protection of myocytes from oxidative stress. Sirtuins are members of a large family of deacetylases that, together with acetylases, form one of the most important and dynamic mechanism of modulation of histones and proteins. It is likely that their beneficial effects depend on the maintenance of the efficiency of energy metabolism and on the activation of FOXO to insure protection from oxidative stress (9,11). Table 1 summarizes the characteristics of sirtuins and underlines those involved in cardiac protection.

3.3. Mitochondrial DNA (mtDNA) mutations

Mitochondria, producing large amount of oxygen reactive metabolites and containing insufficient detoxifying activity (mt Mn-SOD), accumulate mutations in their mtDNA, transmitting these mutations to their lineage, which disappear only when the cells die. Therefore, in post-mitotic tissues mutated mtDNA accumulated with a resultant abnormal synthesis of mitochondrial proteins resulting in altered electron transport, uncoupling of oxidative phosphorylation, a sharp decrease in ATP synthesis and overproduction of oxygen metabolites. Since cardiomyocytes contain a large number of mitochondria, this represents one of the most important factor in ageing of cardiomyocytes (12).

3.4. Impairment of DNA repair

Another important target of free radicals are the proteins of the DNA repair systems. Their inactivation reduces the ability of the cell to correct errors during DNA synthesis, and to correct mutations produced by mutagens, including free radicals. An accumulation of mutations occurs in the proliferating cells leading to either cell transformation (cancer) or to cell death, in post-mitotic cells, such as myocytes or neurons, mutated proteins interfere with the normal life of the cell leading to degradation of function, accumulation of lipofuscins and finally to cell death (6).

3.5. Accumulation of lipofuscins

Lipofuscin particles are yellow-brown, autofluorescent pigment granules composed of oxidized proteins, abnormal proteins and lipid residues which cannot undergo definitive lysosomal digestion. Lipofuscins represent an indirect sign of cell senescence (wear and tear pigment) and contain other indigestible materials, including iron, copper and zinc. Since iron and copper catalyze the lysosomal generation of oxygen species (Fenton reaction), peroxidation of lysosomal membranes occurs leading to the intra/extracellular release of lysosomal enzymes (13). Moreover, lipofuscin accumulation, engulfing the phagolysosomal

system, may result in depressed autophagy and malfunctioning of organellar and supramolecular turnover (14).

3.6. Shortening of telomeres

Telomeres are abnormal in aged cells and are repetitive DNA sequences associated with proteins located at the ends of each chromosome. Chromosomal caps formed by telomeres inhibit end-to-end fusion of chromosomes, preventing their degradation and/or the recognition of chromosome ends as DNA breaks by damage signaling systems (15). Telomeres are considered indicators of biological age since they progressively shorten during each cell cycle (Hayflick limit) (16). DNA polymerases are unable to completely replicate telomeric DNA and, when telomeres reach a critical shortening, also genomic DNA cannot be replicated, losing gene information and leading to apoptosis and tissue senescence (15,16). Telomeres shortening may be considered the physiological numerator of cell cycles and thus determine the life limit of a specific cell lineage. Telomerase, an enzyme able to prevent telomere shortening in embryonic and adult stem cells is active. Telomerases add TTAGGG repeats to chromosomal ends thus maintaining or increasing telomeres length (17). In humans telomerase activity has been demonstrated in cancer cells, being responsible for increased proliferative potential and immortalization (18). Telomerase activity is increased by HIF-1 α in hypoxic conditions and helps repair tissue damaged by hypoxia (19). Coronary artery disease (CAD) has been associated with telomere alterations (20–22). Telomere length in white blood cells (WBC) from CAD patients is significantly reduced when compared with that from healthy patients (20). It has also been shown in CAD patients that endothelial cells derived from atherosclerotic plaques have shorter telomeres when compared with endothelial cells isolated from vessels not involved in atherosclerotic processes (21,22). Similarly, telomeres are shorter in WBCs of patients affected by type I (23) and type II (24,25) diabetes, hypercholesterolemia and low HDL levels (26–28), than in healthy controls. The relationship between hypertension, insulin resistance and oxidative stress with telomere length in a cohort of patients from the Framingham Heart Study indicates that hypertensive subjects exhibited shorter telomere (TRF, terminal restriction fragment) length when compared with normotensive patients (29). Benetos *et al.* also reported that shorter telomere length in WBC is associated with a higher probability to develop carotid artery atherosclerosis in the presence of chronic hypertension (30). A relationship has been demonstrated between telomere length and mortality in patients aged 60 or older (30). Other factors, such as socioeconomic status (31) and psychological stress (32,33), have been associated with telomeres length and telomerase activity. Taken together, these findings suggest a relation between telomeres length and the classical risk factors for CHD. Therefore, it has been proposed that telomere length could be considered a predictor of CHD events and an useful parameter to identify patients who could benefit from statin treatment (34).

Aged cardiomyocytes show a reduction in telomere length, strongly suggesting a role in heart failure. Evaluating telomere length in endomyocardial biopsies and in circulating leukocytes and comparing healthy controls to patients with heart failure has demonstrated that telomeres are shorter in patients affected by dilated cardiomyopathies and heart failure (4,35–39). *In vitro* studies in cultured rat cardiomyocytes and in human myocardium from

patients with heart failure show that apoptosis is associated with the defective expression of the telomere repeat-binding factor TRF2. In addition, down-regulation of TRF2 leads to telomere attrition and Chk2 activation; in contrast, up-regulation of TRF2 appears to confer protection from oxidative stress (40). *In vitro* experiments demonstrated that statin therapy enhances TRF2 levels in endothelial progenitors, suggesting the basis for new therapeutic strategies in the treatment of cardiovascular disease (41).

Therefore, oxidative stress plays a central role in ageing since free radicals induce somatic mutations in nuclear and mitochondrial DNA, alter protein structure facilitating their proteosomal degradation, and damage cellular membranes by lipoperoxidation. All these changes progressively degrade cardiomyocytes thereby losing function and, ultimately, leading to cell death by either necrosis or apoptosis.

3.7. Cardiac activation and conduction system

In elderly a sinus nodal disease may be present due to various ageing process occurring at the cellular level composing the sinoatrial node (P cells or pacemaker cells, transitional cells, Purkinje cells). These ageing process include apoptosis (only 10% of P cells are left in 70 year olds), substitution with adipose or connective tissue, and deposition of amyloid, collagen and other fibrils (42). These structural changes occur at the level of the atrioventricular node and bundle of His and to a greater extent within the bundle branches (42). With ageing, the action potential and thus the duration of contraction are prolonged due to the prolonged release of cytosolic Ca^{2+} . The prolongation of the action potential is due to deceleration of the deactivation rhythm of L-type Ca^{2+} channels and the decreased outflow of K^{+} (43). Ca^{2+} reuptake from the sarcoplasmic reticulum (SERCA Ca^{2+} pump) is decreased, while the activity of the $\text{Na}^{+}/\text{Ca}^{2+}$ exchanger is increased. Ageing can affect the efficiency of Ca^{2+} spark signaling in cardiomyocytes, altering the pulsatile nature of Ca^{2+} and degrading cardiac function (43). These changes in the Ca^{2+} cycle influence myocardial relaxation and are responsible for the deceleration of the premature diastolic filling rhythm, which characterizes ageing.

3.8. Ageing and cardiac stem cells

Adult cardiac stem cells (CSCs) are a multipotent lineage, able to differentiate into cardiomyocytes, endothelial and smooth muscle cells. When injected into the rat infarcted myocardium, CSCs repair necrotic tissue, apparently restoring cardiac function (44). The origin of CSCs is unclear, although it appears that they have an extra-cardiac origin and migrate to the myocardium in post-natal life (45). The number of CSCs in the myocardium is low under normal conditions, but increases in response to damaging stress such as myocardial infarction (45,46) and aortic stenosis (47). Many cellular and biological aspects of CSCs remain unclarified, including their origin, the mechanism of their differentiation, their effective functional integration into an adult tissue and their precise role in the maintenance and repair of adult myocardium.

Both the quantity and the age-related quality of CSCs appear important for their biological activity. In older humans CSCs are to be functionally impaired, thus contributing to heart failure (48).

4. EFFECTS OF PHYSICAL ACTIVITY ON THE BIOLOGICAL MECHANISMS OF CARDIAC AGEING

4.1. Oxidative stress and telomeres

Molecular mechanisms through which physical activity exerts its beneficial effect over almost all age-related alterations in humans may be elucidated by exploring sirtuin activity in target-tissues (Table 1). Sirtuin activity increases with physical activity and has an evident beneficial effect on post-mitotic tissues/cells, such as cardiomyocytes, skeletal myocytes, neurons, and sensory cells thereby either preventing or slowing typical age-related diseases of these tissues (9).

Regular exercise increases the expression and the activity of SIRT1 and thus decreases the level of oxidative damage through activation of FOXO and thereby, increasing the number of antioxidant molecules. Sirtuins are activated by physical activity (49).

The action of SIRT1 on cardiac and skeletal striated muscle has been well characterized. In KO mice heart malformations, decreased resistance to paraquat-induced apoptosis and premature death are present. The cardiac-restricted overexpression of SIRT1 influences muscle mass, deacetylating MyoD (hypertrophy), stem cell recruitment after injury (dystrophy or infarct) and facilitates myocardial tissue and function recovery.

Myocardial tissue, similarly to other tissues, accumulates oxidative damage with ageing. Regular exercise, increasing the expression and the activity of SIRT1, decreases oxidative damage through the activation of FOXO, thereby increasing a number of antioxidant molecules. Myocardiocytes are also protected from abnormal inflammation and from age-related cardiomyopathy.

In humans SIRT3 has been associated with longevity and appears to be involved in the protection of myocardiocytes from oxidative stress. It is likely that most of the of the beneficial effects depend on the maintenance of the efficiency of energy metabolism and on the activation of FOXO for the protection from oxidative stress (9,11).

SIRT4 catalyzes ADP-rybosylation of many mitochondrial proteins, including glutamate dehydrogenase (involved in energy metabolism), insulin degrading enzyme (a protease that controls the level of insulin) and adenine nucleotide translocators (ATP synthesis) (9).

SIRT7 increases stress resistance of cardiomyocytes and prevents apoptotic and inflammatory cardiomyopathy in mice. In SIRT7 KO mice decreased resistance of the myocardium to genotoxic and oxydative stress and increased susceptibility to apoptosis has been reported (9). Table 1 summarizes the characteristics of Sirtuins i.e. Class III Deacetylases.

Sirtuins mediate the effects of resveratrol. Resveratrol is a small molecule that mimics the effects of physical activity conferring protection against CVD (49). Resveratrol pretreatment protects myocardium and limits cell death during acute ischemia/reperfusion damage. This effect is due to the sirtuin-mediated activation of PPAR α , a transcription factor that controls

the expression and the activity of both the inducible and endothelial isoforms of NOS, increasing NO production (49). Inhibiting NOS results in the abolishing of the beneficial effects of resveratrol on ischemic damage (49). Finally, resveratrol upregulates sarcoplasmic calcium ATPase, thereby improving cardiac function in diabetic cardiomyopathy (11).

Resveratrol provokes vasorelaxation *in vitro* and lowers blood pressure in obese Zucker rats and in various experimental models of hypertension. It is able to restore acetylcholine-dependent relaxation of aortas from both obese and aged animals: this effect seems to be mediated by NO signaling (49,50). Resveratrol, in vessel tissues, upregulates the expression NADPH oxidase, the major producer of oxygen radicals, in vessel tissues thus protecting from oxidative stress and maintaining active NO signaling.

Resveratrol suppresses NADPH oxidase in vasculature activating SIRT1 and thus inhibiting NF κ B. Overexpression of SIRT1, activating PGC-1 α in endothelial cells, further suppress NADPH oxidase expression.

Resveratrol inhibits platelet aggregation both *in vitro* and *in vivo*, in normal mice and hypercholesterolemic rabbits. Platelet aggregation is impaired by the inhibition of Mitogen-activated protein kinase (MAPK) signaling of phosphoinositol metabolism and by the high levels of cGMP due to NO signaling, however it is still unclear the precise mechanism by which an increased activity of SIRT1 is able to interfere with all these pathways. Resveratrol, similarly to low-dose aspirin, could be responsible for an irreversible inhibition of cyclooxygenase I activity resulting in a decreased production of thromboxane A2 and other arachidonic acid metabolites by activated platelets, thus weakening and/or blocking complete platelet aggregation and efficient vasoconstriction (49,50).

Leukocyte telomere length is positively associated with increasing levels of physical activity (51). Physical activity prevents cellular senescence regulating telomere-stabilizing proteins in mice and in humans. Physical activity also protects from apoptosis in stressed endothelial cells (52), leukocytes of marathon runners (10), cardiomyocytes and skeletal myocytes of rats running to exhaustion (53). While moderate physical activity has been shown to be beneficial for the maintenance of telomere length, intense physical activity can be detrimental (54). Interestingly, similar results have been obtained studying the effect of physical exercise on the immune system (the Exercise Immunology). Moderate exercise increased the immune response and reduced the risk of infection as compared to both low and intense exercise (55). In conclusion, the relationship between exercise and telomere length requires further studies. Radak *et al.* analyzed telomerase activity in skeletal muscle of rats under regular strenuous exercise and found that enzyme was independent of exercise training level (56).

4.2. Effect of physical exercise on cardiac and skeletal muscle

Skeletal muscle, myocardium and some nervous tissue should not be considered as classical stable post-mitotic tissue (57). In skeletal muscle, satellite cells, located between the basal lamina and the muscle fibers, can proliferate and differentiate to form adult myocytes (58). Their proliferation is necessary for routine maintenance, hypertrophic adaptation, and repair of adult muscle. Despite satellite cells being able to differentiate from hematogenous stem

cells, it appears that they constitute a completely independent niche. In fact, when bone marrow-derived circulating cells with myogenic potential are inactivated by localized irradiation, muscle regeneration and function is unaffected (59). Ageing is associated with a significant decline in the total mass, strength, and endurance of skeletal muscles (60). Physical exercise can induce a proliferation of satellite cells (61–64). Although the proliferative potential of satellite cells is conditioned by their telomere length, contrasting results suggest that telomere length in satellite cells does not reflect the number of cell divisions. This could be due to an unknown alternative mechanism that controls telomere length *in vivo* (57).

Many protective effects of physical exercise have been described in cardiac muscle. Both short and long-term running increases cardiac telomerase activity and expression of TERT and TRF2 protein and reduces the expression of proapoptotic proteins Chk2 (cell cycle checkpoint kinase 2), p53, and p16. Interestingly, after 6 months, TRF2 and TERT expression remained elevated, while the expression of Chk2, p53, and p16 was decreased. Physical activity increases cardiac-specific expression of IGF-1 (paracrine insulin-like growth factor 1); this is an important survival factor, which, through the activation of Akt, induces the activation of many transcription factors, including NFkB, and the up-regulation of a set of genes including sarcomeric proteins, NOS, and mitochondrial genes, thereby contributing to the maintenance and to the hypertrophy of skeletal muscle. Interestingly, an overexpression and activation of SIRT1 and SIRT3, induced by physical exercise (10), have been demonstrated both in humans and in animal models (10) associated with a number of beneficial effects on basic skeletal muscle and myocardial maintenance (11). Doxorubicin treated mice develop an apoptotic cardiomyopathy which is either mitigated or reversed by physical exercise through the up-regulation of telomere-stabilizing proteins and the reduction of doxorubicin-induced p53 expression, in this way preventing apoptosis (65), probably through the overexpression and activation of various sirtuins. Taken together, these observations suggest that the protective effects of physical activity on cardiomyocytes is achieved through typical anti-ageing mechanisms such as the prevention of apoptosis and the increased ability in repairing and substituting damaged molecules (66).

4.3. Effects of physical exercise on cardiac hypertrophy

The relationship between physical exercise and cardiac hypertrophy is well documented (67). Hypertrophy is manifest by an increase in cardiac mass which occurs in response to both pathological and physiological stimuli. It is characterized by increases in both major and minor axis of myocardiocytes and by an increase of myofibrillar and mitochondrial mass. Myocardiocyte hypertrophy represents the adaptation of the cell to an increased wall stress and to an increased demand on contractile work. Physiological hypertrophy typically occurs in trained athletes with preserved sarcomeres/mitochondria ratio and well preserved architecture of contractile proteins into well-oriented sarcomeres. Pathological hypertrophy (also called concentric hypertrophy) occurs in patients with hypertension, with valvular defects and with loss-of-function mutations of sarcomere-related proteins. Typically, there is a continuously increasing demand on contractile work, which leads to a pathological hypertrophic adaptation. This consists in the abnormal expression of sarcomeric proteins, including embryonic and foetal isoforms, abnormal assembly of the sarcomeric proteins,

deviating from the vector of the contraction and leading to an abnormal architecture of the cell. Therefore, concentric hypertrophy of myocytes is characterized by a sharp increase of both long and short axis of myocytes, by an increased ratio sarcomeres/mitochondria, by sarcomeric disarray with a decrease in contractile efficiency, by the expression of immature contractile protein isoforms and by many electrical abnormalities, such as decreased outward currents.

Increased total volume of cardiomyocytes produces an increase in sarcolemmal area which, in turn, may determine disorders in membrane ion currents and in excitation-contraction coupling. One of the most important changes observed in all grades of hypertrophy is a prolonged action potential duration. This may result either from a decreased outward current and/or an increased inward current. The first represents the major electrical alteration of membrane currents that occurs in hypertrophy. The altered outward K⁺ current induces a delayed repolarization which, in turn, determines a prolonged action potential duration, frequently triggering arrhythmias (68–70). However, more studies are necessary in order to define the precise mechanisms underlying arrhythmias in hypertrophy, either spontaneous or exercise-induced.

4.4. Physical activity and EPCs

Studies to assess the effect of exercise on endothelial progenitor cells (EPCs) levels provide contrasting results. Adams *et al.* (71) demonstrated an age-dependent increase in circulating EPCs in patients affected by symptomatic CAD, responding to exercise-induced myocardial ischemia. This increase appeared related to/ and preceded by an increase in plasma VEGF, likely associated to the activation of the transcription factor HIF1 α by the hypoxic stimulus. In contrast, Thijssen *et al.* (72) examined the effect of long-term physical exercise on the number of hematopoietic stem cells (HSC) and EPCs. Young athletes (18–28 year old) were compared with older men over an 8-week period endurance training. Older subjects showed significantly lower baseline and exercise-induced levels of HSCs and EPCs than the younger athletes; however in both groups, acute exercise significantly increased HSCs, but not EPCs. Interestingly, the increase in numbers of HSCs was reduced in older men, suggesting that ageing may reduce the acute exercise-induced recruitment and/or production HSCs. Sarto *et al.* (73) demonstrated that patients with chronic heart failure in response to aerobic exercise exhibited a parallel increase of EPCs and of VEGF plasma levels. Laufs *et al.* (74) showed that intensive and moderate physical exercise in 25 healthy volunteers for 30 min, increased circulating EPCs. Luk *et al.* (75) showed that more intense habitual physical activity was associated with higher brachial artery flow-mediated dilation and EPCs count. In this study 116 patients (67.8 $\pm$ 9.5 years; 81% male) with stable CAD and preserved left ventricular ejection fraction $\geq$ 45% were studied. Interestingly, only flow-mediated dilation significantly correlated with increased physical activity, but not EPCs, suggesting that physical activity improves endothelial function not only through EPCs recruitment, but also through other mechanisms, such as sirtuins activation and overexpression (76).

4.5. Physical activity and CSCs

Data on the effect of physical exercise on CSC number is scarce. Brehm *et al.* (77) analyzed the effect of regular exercise in promoting the mobilization and improving the functional

activity of CSCs in patients with recent myocardial infarction. Patients undergoing a physical exercise program demonstrated that the number and migration capacity of cardiac progenitors cells increased significantly whereas the BNP level decreased.

5. EFFECTS OF PHYSICAL ACTIVITY ON AGEING RELATED CARDIAC DYSFUNCTION

5.1. Cardiac remodelling

With ageing a moderate increase in the thickness of the left ventricular (LV) wall (78) and concentric hypertrophy of myocytes (79) occur. Mild hypertrophy may be due to an increase in systolic blood pressure, and neurohormonal or other trophic factors. Hypertrophy involving interventricular septum leads to LV outflow obstruction and thus to a further increase in afterload. The wall thickening of LV and its reduction in length produces a more spherical ventricle. Dextral shift of the ascending aorta also contributes to this remodeling (80). Systolic function and cardiac output may remain normal (81). In contrast, LV diastolic function may be abnormal in older people.

The aforementioned changes in the calcium cycle influence myocardial relaxation and explain the deceleration of the premature diastolic filling rhythm, typical of aging. Ultrasound and radionuclide analysis have shown a 50% reduction of velocity of the early phase of LV filling, between the third and ninth decades of life, with an equivalent increase in the late diastolic filling phase (82). The delayed relaxation, combined with the decreased compliance of aged myocardium, leads to an increase in end-diastolic pressure, a decrease in the early passive diastolic filling phase, and an increase in the late active phase of diastolic filling. Possible mechanisms that explain the reduction of velocity of the early diastolic filling include the accumulation of ECM, fibrosis and the deceleration in calcium activation from preceding contraction (83). The combination of decreased diastolic pressure and LV hypertrophy predisposes the individual to subendocardial ischemia and to fibrosis in the intermediate tissue. Ischemia further worsens the LV contraction (left and up shift of pressure-volume curve).

Consequently, compliance, and filling of the LV are reduced, with an increase of the pressure in the left atrium and pulmonary veins. Thus, a vicious circle exists that leads to diastolic heart failure, the most common form (40–80%) of heart failure in elderly people (84). These changes can be prevented with prolonged and sustained endurance exercise. Recent evidence demonstrated that age-related impairment in LV function could be partly prevented by regular endurance training (85). The mechanism(s) include preservation of viscoelastic myocardial properties and pericardial size, as well as optimization of chamber geometry. Prolonged endurance exercise is known to result in eccentric ventricular hypertrophy, ie, a balanced enlargement of ventricular mass and dimensions. These adaptations lead to improved cardiac performance without apparent change in contractility and are largely explained by enhanced diastolic function (86).

Prolonged exercise training may also elicit its effect through the maintenance of vascular elasticity and thus smaller arterial load. Arterial elastance is inversely related to vascular

compliance and is a more sensitive marker for arterial load than total peripheral resistance (87). Decreased vascular compliance is associated with ageing and hypertension (88,89) and, recently, has been associated to heart failure with preserved ejection fraction (90) and to cerebrovascular events (91). Endurance training preserves vascular elasticity with ageing (92), thereby preventing cardiac adaptive changes, including myocardiocyte ultrastructural degradation and focal proliferation of matrix, preventing myocardial stiffness. Therefore, preserving ventriculo-vascular coupling is a key component in the fight against hypertension and heart disease (88).

5.2. Physical activity in preventing arrhythmias

Hypertrophy is one of the possible mechanism underlying arrhythmias that occur in both trained and sedentary subjects. Normally, the cardiac rhythm is regulated by the autonomic nervous system (ANS), and the age-related malfunction of the ANS is reflected by the decreased variability of cardiac rhythm (93). Changes in parasympathetic and/or sympathetic regulation of the heart can contribute significantly to the induction of different kinds of arrhythmias, particularly ventricular tachyarrhythmias. Heart rate variability is considered a valid index of cardiac vagal activity (94–96). A wide range of cardiovascular risk factors have been linked to a reduction in heart rate variability. These include hypertension (97–99), diabetes (100–103), carotid atherosclerosis (104), smoking (105–107), heart failure (108,109) and myocardial infarction (110–112). Subjects who show the greatest reduction in heart rate variability also have a higher risk of sudden death following an infarct (113). In contrast, in patients who exhibit a high heart rate variability, mirroring a well preserved vagal tone the risk of sudden death is sharply reduced (110,111). These results suggest that parasympathetic tone plays a protective role, contrasting to the development of sudden cardiac death. An enhanced cardiac sympathetic activity increases the risk of sudden death provoked by a lethal cardiac arrhythmia (114,115). Therapeutic interventions to augment parasympathetic tone, at least in animal models, have been shown to be useful in reducing possible lethal arrhythmias (116). The use of this strategy in humans is strongly hampered by the gastrointestinal side-effects of cholinergic agonists. Finally, interventions that reduce cardiac sympathetic activity may play also a protective role against malignant arrhythmias (117–123).

Endurance exercise training induces an increase in cardiac parasympathetic tone combined with a reduction in sympathetic activity (124–131). Endurance exercise training increases cardiac parasympathetic tone and decreases sympathetic activity (132–136). Both in humans and animals, the heart rate at submaximal workloads was reduced in trained individuals compared with sedentary controls (136–140). A resting bradycardia is a well-established consequence of exercise training and is, in fact, used as a marker that the exercise-trained state has been achieved (134,136,139). Both acetylcholine content and choline-acetyltransferase were increased in the hearts of trained rats compared to the control animals (141,142). In humans, exercise training during recovery from myocardial infarction has been reported to increase heart rate variability (143). In a similar manner, exercise training has been shown to attenuate reductions in heart rate variability in patients with either hypertension (144) or heart failure (143). These data suggest that endurance exercise training

can elicit changes in cardiac autonomic control that attenuate the cardiac autonomic remodeling induced by myocardial infarction.

Recent studies have analysed the effects of exercise training on both the parasympathetic and the β -adrenoceptor regulation of cardiac function in normal animals, aged animals, and animals with hypertension, in the presence of either a reduction in or no change in β_1 -adrenoceptor density (145–148). MacDonnell *et al.* (148) demonstrated that physical activity improves the inotropic response to β -adrenoceptor stimulation in spontaneously hypertensive rats. Abnormal repolarization (due to altered K^+ currents) or intracellular calcium regulation could act individually or in concert to decrease cardiac electrical stability and increase the propensity to arrhythmias and sudden cardiac death. Interestingly, hypertensive patients treated with beta-blockers do not show an impairment in the cardiovascular benefits of endurance training (149). Noteworthy, the right level of exercise seems to be important in order to produce a protective effect. In fact, an excessive strenuous exercise may have detrimental effects, increasing sympathetic activity and reducing parasympathetic tone (150). The role of physical activity in preventing lethal arrhythmias is particularly evident in high-risk populations, such as patients recovering from myocardial infarction (151–153). The cellular and molecular mechanisms responsible for causing arrhythmias and how exercise protects against them are not completely understood. Intracellular calcium dysregulation may play a role both in contractile dysfunctions and arrhythmogenesis (154–156). Intracellular calcium regulation, ion channels changes (157) and autonomic neural dysfunctions may also play a role, singularly or in concert, to decrease cardiac electric stability, leading to the development of lethal arrhythmias. Recent evidence suggests that various sirtuins, through new gene expression facilitating myocardial repair and function, can have a central role in preventing arrhythmias and rescuing infarcted myocardium (158).

6. ARTERIAL AGEING

With ageing, structural changes occur in the vessels, influencing cardiac function and the blood supply of peripheral tissues (159). Age-related arteriosclerosis macroscopic changes include: 1) dilation and convolution of large arteries (dilation is more severe in the aorta proximal to the myocardium and in its large branches, but smaller in the muscle arteries); 2) enlargement of the lumen and thickening of the vessel wall (160). However, precise factors and mechanisms involved in these age-related changes are not completely understood. Notably, the increased thickness of vessel wall constitutes an independent risk factor for cardiovascular events (160). Microscopically, endothelial cells become irregular in shape and increase in height (metaplasia). Hypertrophy, proliferation and migration of smooth muscle cells occurs in the intima and subendothelial space, with collagen accumulation, decrease and fragmentation of elastin, and deposits of hydroxiapatite, which leads to calcification. ECM is increased, containing more mature glycosaminoglycans and collagen polymers, which decreases vessel compliance, favouring peripheral resistance. The compliance of the common carotid artery decreases by approximately 40–50% from age 25 to 75 years. In the arterial wall of older people it is evident a chronic aspecific inflammatory process occurs. This is manifest with an increase in T lymphocytes, monocytes and activated macrophages, metalloproteinase activity, substantial presence of growth factors, Th1

cytokines and ACE (161). At the endothelial level, expression of vasoconstrictive factors (such as endothelin-1 and angiotensin-II) increases, while vasodilator molecules (such as nitric oxide and estrogens) decrease (162).

Age-related arteriosclerosis is distinct from atherosclerosis associated to an abnormal homeostasis of cholesterol and saturated lipids. Arteriosclerosis results in stiffening of the large arteries and an increase of pulse wave velocity (PWV), which is a reliable and widely used index of arterial stiffening (163,164). The arterial waveform (165) shows an enhancement of the early systolic portion of the wave as a result of the earlier return of the reflected wave from the periphery due to the increased pulse wave velocity. This early systolic enhancement increases left ventricular afterload and predisposes to disturbed myocardial oxygen demand/supply balance (163,164).

7. EFFECT OF PHYSICAL ACTIVITY ON ARTERIAL AGEING

7.1. Structure and function (vascular remodeling)

The age-related increase in arterial stiffness is also responsible for changes in arterial pressure. Systolic blood pressure increases progressively, especially after the sixth decade, while diastolic pressure reaches a plateau after the fifth decade and decreases slightly after the sixth. These changes result in a widening of pulse pressure observable from the sixth or seventh decade onwards (163). The resultant pulsatile stretch of the large arteries endangers their wall integrity. Importantly, arterial stiffening (as indicated by its “gold standard” index PWV) is an independent predictor of cardiovascular morbidity and mortality, as well as of total mortality, in a wide array of populations, including patients with hypertension or CAD (coronary artery disease), as well as the general population (163,164). Arterial ageing may be slowed by adopting a healthy lifestyle. Any physical activity, including any form of recreational exercise, has favourable effects on retarding age-related arterial stiffening (163,164).

Physical activity activates sirtuins and resveratrol, provokes vasorelaxation *in vitro* and lowers blood pressure in obese Zucker rats and in various experimental models of hypertension. It is able to restore acetylcholine-dependent relaxation of aortas from both obese and aged animals: also this effect seems to be mediated by NO signaling (49,50). Resveratrol is able to upregulate the expression NADPH oxidase in vessel tissues, thereby protecting from oxidative stress and maintaining active NO signaling.

Resveratrol probably suppresses NADPH oxidase in vasculature activating SIRT1 and thus inhibiting NF κ B. Overexpression of SIRT1, activating PGC-1 α in endothelial cells, further suppresses NADPH oxidase expression.

Resveratrol inhibits platelet aggregation *in vitro* and *in vivo*, both in normal mice and hypercholesterolemic rabbits. It is well known that platelet aggregation is impaired by the inhibition of Mitogen-activated protein kinase (MAPK) signaling, by phosphoinositol metabolism and by the high levels of cGMP due to NO signaling, however it is still unclear the precise mechanism by which an increased activity of SIRT1 is able to interfere with all these pathways.

Physical exercise when performed at a regular basis in particular aerobic exercise/fitness, is associated with enhanced vascular function and reduced risk of CVDs. The beneficial effects of regular resistance exercise (i.e., strength training, weight lifting, etc.) on arteries and cardiovascular disease is less evident. These observations suggest that an exercise life-style may exert its beneficial effects on general physiological functions reducing age-related CVD at least in part by preventing adverse changes in the structure and function of arteries. The initial clue that habitual aerobic exercise might attenuate age-associated increases in large elastic artery stiffness came from the Baltimore Longitudinal Study of ageing, that showed older male endurance athletes had a lower aortic PWV, increased index and systolic blood pressure as compared to sedentary controls (166). Follow-up investigations showed that age-associated reductions in carotid artery compliance were ~50% as great in healthy men and women who performed habitual aerobic exercise compared to sedentary adults (167). Daily brisk walking for at least 3 months improved carotid artery compliance in previously sedentary middle-aged/older men (167) to levels observed in age-matched endurance exercise-trained adults, suggesting that even moderate aerobic exercise may produce beneficial effects. A substantial contribution to these beneficial effects of regular exercise came from the prevention of age-related structural changes of the arterial wall (168). Ascorbic acid (and other free radical scavengers) improves carotid artery compliance in sedentary, but not in endurance exercise-trained postmenopausal women (169), suggesting that a reduction in levels of oxidative stress is achieved in the habitually exercising subjects. Improvements in carotid artery compliance in response to regular moderate-intensity exercise are independent of baseline compliance and changes in conventional risk factors for CVDs, body composition, and aerobic fitness (167).

The increased vessel sclerosis results, not only from vessel structural changes, but also from reduced endothelium-dependent vasodilation, which usually is observed in humans with advancing age (170), as is also suggested by a decreased response to acetylcholine, which involves all peripheral vessels participating, including coronary arteries (170). The production of NO is decreased, favouring vasoconstriction (171). Ageing enhances the susceptibility of endothelial cells to apoptotic stimuli, reduces angiogenic and regenerative capacity of the endothelium, decreasing the number and the function of EPCs (172). The endothelial barrier (as determined by the integrity and strength of junctional complexes, especially zonula occludens), is abnormal in aged subjects as compared to younger subjects (171). A number of cellular and molecular mechanisms underlying age-associated are strictly associated with NO decline, produced by eNOS, but have not been fully elucidated. However, upregulation of inducible NOS (iNOS) has been reported, this may lead to the formation of peroxynitrite radicals (ONOO⁻), thus contributing to oxidative damage of endothelium and other vessels (173).

Endothelium-dependent vasodilation is accentuated in middle-aged and older men who regularly perform aerobic exercise as compared with their sedentary peers (174–177), and it is similar to (174, 175), or slightly lower than (176) that of young healthy sedentary subjects. Three months of moderate-intensity aerobic exercise training improves endothelial function in previously sedentary aged healthy individuals (174) and in patients with asymptomatic metabolic syndrome (177). Aerobic physical activity improves endothelial function in middle-aged and aged-patients with CVD, but consistent effects have not been observed in

healthy young men and women with normal baseline function (174). In aged rats aerobic training-induced improvements in endothelium dependent vasodilation and NO synthesis are associated with an overexpression of eNOS (178) and in patients with CAD a SNPs of eNOS having a phosphorylable serine (179). In relation to this, no information is available in aged healthy humans. Acute administration of supraphysiological concentrations of antioxidants (vitamin C) improves endothelium dependent vasodilation in sedentary, but not in endurance exercise-trained, men (167). Trained middle-aged and older adults have lower malondialdehyde (a marker for lipoperoxidation) and a more efficient scavenging capacity as compared with age-matched sedentary adults (180).

7.2. Coronary heart disease

A large number of studies demonstrate that moderate and constant physical activity is associated with a decreased risk of death from coronary disease. A meta-analysis of 32 studies (181) demonstrated an increased risk of death from coronary heart disease (CHD) in subjects with a sedentary lifestyle as compared to those with an active one. Sesso *et al.* (182) followed 12,516 middle-aged and older men from 1977 through 1993 to examine the impact of physical activity on CHD risk, and other coronary risk factors. He showed a clear association between the level of physical activity and reduction in CHD risk. Lee *et al.* (183) analyzed the precise relationship between the intensity (duration and strength) of exercise and CHD risk, demonstrating that the accumulation of shorter sessions of physical activity seemed to have a more beneficial effect on reducing CHD risk than longer and stronger exercise. Similar results have been reported in a study examining the relationship between physical fitness and cardiovascular mortality in 4276 men, aged 30–69 years, with a follow-up of 8.5 years (184). The authors concluded that a lower level of physical fitness is associated with a higher risk of death from CHD and other CVD in clinically healthy men, and that this is independent of other coronary risk factors. Kim *et al.* (185) studied the effect of intensity versus frequency of exercise on lipid levels in patients with CHD. Exercise frequency appeared more important than intensity in improving HDL cholesterol, the LDL/HDL ratio and in lowering the total cholesterol/HDL ratio in these patients. More recently, a meta-analysis has been conducted to quantify cardiorespiratory fitness (CRF) and its relationship with all-cause mortality and both CHD and other CVD, in healthy men and women (186). CRF was estimated as maximal aerobic capacity (MAC) expressed in metabolic equivalent (MET) units. This study showed that individuals with low CRF (<7.9 METs in MAC) had a substantially higher risk of all-cause mortality and CHD/CVD compared with those with intermediate and high CRF (7.9–10.8 and 10.9 METs in MAC, respectively).

Sedentary elderly subjects are characterized by the presence of age-related, oxidative stress-induced endothelial dysfunction (180). Long-term physical training appears to reverse endothelial dysfunction, presumably by preventing oxidative stress, preserving NO availability (187), and preventing the thickening of the intima-media and the fibrosis of the carotid artery wall (188).

Table 2 summarizes the principal age related changes (characteristics) which are positively affected by physical activity as well as the principal tests for each change (characteristic).

8. DISCUSSION

Ageing is characterized by biological, structural and functional changes of the cardiovascular system (Table 2). To summarize, ageing is associated with:

- reduced resistance to oxidative stress, enlargement and hypertrophy of the remaining myocytes,
- thickening of the vascular wall leading to diastolic dysfunction, which predisposes to heart failure,
- increased pulse wave velocity and ejection time delay with increased systolic arterial and pulse pressure,
- endothelial dysfunction predisposing to atherosclerotic disease,
- decreased maximal heart rate, maximal cardiac output and maximal VO₂.

Human and animal data confirm an important beneficial role of exercise in the prevention of the age-induced cardiovascular modifications. In the present review we describe these changes and highlight the effects of exercise on oxidative stress, endothelial function, cardiac and vascular remodeling (Table 2).

The antioxidant role of physical exercise in man is derived mainly from experimental studies. However, some evidence suggests that older athletes have higher antioxidant capacity and lower oxidative stress as compared to older sedentary subjects and that plasma antioxidant capacity and malondialdehyde levels were not different in older athletes when compared to the younger population (180). Although it has been suggested that acute exercise can cause oxidative stress by increasing LDL susceptibility to oxidation or vascular superoxide production, chronic exercise exerts a beneficial effect on oxidative stress by ameliorating the lipid profile, and/or by increasing antioxidant defenses (181–183).

Sirtuines can be considered as mediators of the beneficial effects of physical activity in cardiovascular physiology and pathology (table 1). A pertinent and important issue is the relationship between physical activity and quality or length of human life. Regular physical activity reduces the risk of cardiovascular disease, thromboembolic stroke, arterial hypertension, type 2 diabetes mellitus, osteoporosis, obesity, colon cancer, breast cancer, anxiety, and depression. Physical activity reduces the risk of falls and injuries from falls (189), prevents or mitigates functional limitations (190,191), and is effective therapy for many chronic diseases. Clinical practice guidelines identify a substantial therapeutic role for physical activity in coronary heart disease and arterial hypertension (192), peripheral vascular disease (193), type 2 diabetes (194), obesity (195), elevated cholesterol (192), osteoporosis (196), osteoarthritis (197), claudication (198), and chronic obstructive pulmonary disease (199). Finally, a role for physical activity exists in the management of depression and anxiety disorders (200), dementia (201) and pain (202). There is some evidence to suggest that physical activity prevents or delays cognitive impairment (203), disability (204) and improves sleep (205).

Recent epidemiologic studies support an independent and inverse association between physical activity (individual fitness status) and mortality in apparently healthy individuals and diseased populations (206–210). These benefits are realized at relatively low fitness levels and, in some studies, increase with higher physical activity patterns and/or fitness status in a dose-response manner. (208) The risk reduction is at least in part attributed to the favorable effect of exercise/physical activity on cardiovascular risk factors, namely, blood pressure, diabetes mellitus and obesity.

Table 3 summarizes the inverse relationship between physical activity and mortality/heart attack risk.

However, the majority of these studies are prospective observational studies and no randomized trial has been conducted (211). Some considerations must be clarified. An exercise volume threshold can be defined beyond which a significant reduction in mortality risk occurs. Such thresholds appear to be at caloric expenditure of approximately 1,000Kcal per week was defined as the threshold for an average reduction of 20% to 30% in mortality risk (207,208). Further minor reductions in risk are observed with higher energy expenditure. Physical activity intensity higher than 3500 Kcal/week seems to be associated to a mild increase in mortality risk (207). The benefit of a moderate physical activity occurs also in twins, therefore it is recommended even in case of a relatively low genetic-familial risk (212). The independent contribution of the exercise components intensity, duration, and frequency to the reduction of mortality risk is not clear and the need for more research to better understand the contribution of each component is emphasized (209).

Although the physical activity-mortality relationship is now well established, information on the intensity, duration, and type of physical activity is still largely speculative. An exercise intensity threshold of about 6METs for a reduction in risk has been suggested by some (213). Others have shown an independent effect of exercise type, intensity, and duration on the risk for coronary heart disease. (214).

Finally, it is not yet clear whether physical activity is related to the risk of stroke as it is to the risk of CHD (211).

9. CONCLUSION

Many cardiovascular changes occur as a result of ageing. These changes predispose an individual to different diseases. Physical activity interacts with all the principal pathophysiologic mechanisms involved. New mechanisms like sirtuins related to this interaction have been described in experimental studies. It is likely that study translation to humans will improve the understanding and management of this interaction. Furthermore the validation of blood tests like TOSCA and telomerase length will help define the parameters of optimal physical exercise in each individual. At present a moderate intensity activity (1000 to 2000 Kcal/week) shows a clinical benefit. Because noninvasive and relatively cheap tests are available for detecting and monitoring the cardiovascular changes as well as the effect of physical exercise, each ageing patient undergoing an exercise regimen should be monitored to assess the progress of cardiovascular change.

References

1. Kokkinos P, Myers J. Exercise and physical activity: clinical outcomes and applications. *Circulation*. 2010; 122:1637–1648. [PubMed: 20956238]
2. Hosoda T, Kajstura J, Leri A, Anversa P. Mechanisms of Myocardial Regeneration. *Circ J*. 2010; 74:13–17. [PubMed: 19920358]
3. Anversa P, Leri A, Kajstura J. Cardiac regeneration. *J Am Coll Cardiol*. 2006; 47:1769–1776. [PubMed: 16682300]
4. Chimenti C, Kajstura J, Torella D, Urbanek K, Heleniak H, Colussi C, Di Meglio F, Nadal-Ginard B, Frustaci A, Leri A, Maseri A, Anversa P. Senescence and death of primitive cells and myocytes lead to premature cardiac aging and heart failure. *Circ Res*. 2003; 93:604–613. [PubMed: 12958145]
5. Fleg JL, O'Connor F, Gerstenblith G, Becker LC, Clulow J, Schulman SP, Lakatta EG. Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. *J Appl Physiol*. 1995; 78:890–900. [PubMed: 7775334]
6. Bokov A, Chaudhuri A, Richardson A. The role of oxidative damage and stress in aging. *Mech Ageing Dev*. 2004; 125:811–826. [PubMed: 15541775]
7. Fares E, Howlett SE. Effect of age on cardiac excitation-contraction coupling. *Clin Exp Pharmacol Physiol*. 2010; 37:1–7. [PubMed: 19671063]
8. Thompson LV. Oxidative stress, mitochondria and mtDNA-mutator mice. *Exp Gerontol*. 2006; 41:1220–1222. [PubMed: 17126516]
9. Haigis MC, Sinclair DA. Mammalian Sirtuins: Biological Insights and Disease Relevance. *Ann Rev Pathol*. 2010; 5:253–295. [PubMed: 20078221]
10. Marfe G, Tafani M, Pucci B, Di Stefano C, Indelicato M, Andreoli A, Russo MA, Sinibaldi P, Manzi V. The effect of marathon on mRNA expression of anti-apoptotic and pro-apoptotic proteins and sirtuin family in male recreational long-distance runners. *BMC Physiology*. 2010; 10:1–9. [PubMed: 20113508]
11. Pillai VP, Sundaresan NR, Jeevanandam V, Gupta MP. Mitochondrial SIRT3 and heart disease. *Cardiovasc Res*. 2010; 88:250–256. [PubMed: 20685942]
12. Bodyak N, Kang PM, Hiromura M, Suljoadikusumo I, Horikoshi N, Khrapko K, Usheva A. Gene expression profiling of the aging mouse cardiac myocytes. *Nucleic Acids Res*. 2002; 30:3788–3794. [PubMed: 12202764]
13. Terman A, Gustafsson B, Brunk UT. The lysosomal-mitochondrial axis theory of postmitotic aging and cell death. *Chem Biol Interact*. 2006; 163:29–37. [PubMed: 16737690]
14. Kurz T, Terman A, Gustafsson B, Brunk UT. Lysosomes and oxidative stress in aging and apoptosis. *Biochim Biophys Acta*. 2008; 1780:1291–1303. [PubMed: 18255041]
15. Artandi SE. Telomeres, telomerase, and human disease. *N Engl J Med*. 2006; 355:1195–1197. [PubMed: 16990382]
16. Hayflick I. The limited *in vitro* lifetime of human diploid cell strains. *Exp Cell Res*. 1965; 37:614–636. [PubMed: 14315085]
17. Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. *FEBS Lett*. 2005; 579:859–862. [PubMed: 15680963]
18. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. *Cell*. 1989; 59:521–529. [PubMed: 2805070]
19. Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). *Mol Cell Biol*. 2004; 24:6076–6083. [PubMed: 15199161]
20. Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. *Curr Opin Genet Dev*. 1995; 5:249–255. [PubMed: 7613096]
21. Samani NJ, Boulton R, Butler R, Thompson JR, Goodall AH. Telomere shortening in atherosclerosis. *Lancet*. 2001; 358:472–473. [PubMed: 11513915]
22. Ogami M, Ikura Y, Ohsawa M, Matsuo T, Kayo S, Yoshimi N, Hai E, Shirai N, Ehara S, Komatsu R, Naruko T, Ueda M. Telomere shortening in human coronary artery diseases. *Arterioscler Thromb Vasc Biol*. 2004; 24:546–550. [PubMed: 14726417]

23. Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, Ritchie A, Goddard M, Bennett M. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. *Circ Res.* 2006; 99:156–164. [PubMed: 16794190]
24. Jeanclos E, Krolewski A, Skurnick J, Kimura M, Aviv H, Warram JH, Aviv A. Shortened telomere length in white blood cells of patients with IDDM. *Diabetes.* 1998; 47:482–486. [PubMed: 9519758]
25. Olivieri F, Lorenzi M, Antonicelli R, Testa R, Sirolla C, Cardelli M, Mariotti S, Marchegiani F, Marra M, Spazzafumo L, Bonfigli AR, Procopio A. Leukocyte telomere shortening in elderly Type2DM patients with previous myocardial infarction. *Atherosclerosis.* 2009; 206:588–593. [PubMed: 19464008]
26. Adaikalakoteswari A, Balasubramanyam M, Mohan V. Telomere shortening occurs in Asian Indian Type 2 diabetic patients. *Diabet Med.* 2005; 22:1151–1156. [PubMed: 16108841]
27. Obana N, Takagi S, Kinouchi Y, Tokita Y, Sekikawa A, Takahashi S, Hiwatashi N, Oikawa S, Shimosegawa T. Telomere shortening of peripheral blood mononuclear cells in coronary disease patients with metabolic disorders. *Intern Med.* 2003; 42:150–153. [PubMed: 12636233]
28. Chen W, Gardner JP, Kimura M, Brimacombe M, Cao X, Srinivasan SR, Berenson GS, Aviv A. Leukocyte telomere length is associated with HDL cholesterol levels: The Bogalusa heart study. *Atherosclerosis.* 2009; 205:620–625. [PubMed: 19230891]
29. Demissie S, Levy D, Benjamin EJ, Cupples LA, Gardner JP, Herbert A, Kimura M, Larson MG, Meigs JB, Keaney JF, Aviv A. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. *Aging Cell.* 2006; 5:325–330. [PubMed: 16913878]
30. Benetos A, Gardner JP, Zureik M, Labat C, Xiaobin L, Adamopoulos C, Temmar M, Bean KE, Thomas F, Aviv A. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. *Hypertension.* 2004; 43:182–185. [PubMed: 14732735]
31. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. *Lancet.* 2003; 361:393–395. [PubMed: 12573379]
32. Cherkas LF, Aviv A, Valdes AM, Hunkin JL, Gardner JP, Surdulescu GL, Kimura M, Spector TD. The effects of social status on biological aging as measured by white-blood-cell telomere length. *Aging Cell.* 2006; 5:361–365. [PubMed: 16856882]
33. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, Cawthon RM. Accelerated telomere shortening in response to life stress. *Proc Natl Acad Sci USA.* 2004; 101:17312–17315. [PubMed: 15574496]
34. Epel ES, Lin J, Wilhelm FH, Wolkowitz OM, Cawthon R, Adler NE, Dolbier C, Mendes WB, Blackburn EH. Cell aging in relation to stress arousal and cardiovascular disease risk factors. *Psychoneuroendocrinology.* 2006; 31:277–287. [PubMed: 16298085]
35. Brouillette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, Packard CJ, Samani NJ. West of Scotland Coronary Prevention Study Group. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. *Lancet.* 2007; 369:107–114. [PubMed: 17223473]
36. Van der Harst P, van der Steege G, de Boer RA, Voors AA, Hall AS, Mulder MJ, van Gilst WH, van Veldhuisen DJ. MERIT-HF Study Group. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. *J Am Coll Cardiol.* 2007; 49:1459–1464. [PubMed: 17397675]
37. Leri A, Franco S, Zacheo A, Barlucchi L, Chimenti S, Limana F, Nadal-Ginard B, Kajstura J, Anversa P, Blasco MA. Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation. *EMBO J.* 2003; 22:131–139. [PubMed: 12505991]
38. Fuster JJ, Andrés V. Telomere biology and cardiovascular disease. *Circ Res.* 2006; 99:1167–1180. [PubMed: 17122447]
39. Wong LS, de Boer RA, Samani NJ, van Veldhuisen DJ, van der Harst P. Telomere biology in heart failure. *Eur J Heart Fail.* 2008; 10:1049–1056. [PubMed: 18815070]

40. Oh H, Wang SC, Prahash A, Sano M, Moravec CS, Taffet GE, Michael LH, Youker KA, Entman ML, Schneider MD. Telomere attrition and Chk2 activation in human heart failure. *Proc Natl Acad Sci U S A*. 2003; 100:5378–5383. [PubMed: 12702777]
41. Spyridopoulos I, Haendeler J, Urbich C, Brummendorf TH, Oh H, Schneider MD, Zeiher AM, Dimmeler S. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. *Circulation*. 2004; 110:3136–3142. [PubMed: 15520325]
42. Jones SA. Ageing to arrhythmias: conundrums of connections in the ageing heart. *J Pharm Pharmacol*. 2006; 58:1571–1576. [PubMed: 17331319]
43. Josephson IR, Guida A, Stern MD, Lakatta EG. Alterations in properties of L-type Ca channels in aging rat heart. *J Mol Cell Cardiol*. 2002; 34:297–308. [PubMed: 11945022]
44. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. *Cell*. 2003; 114:763–776. [PubMed: 14505575]
45. Mouquet F, Pfister O, Jain M, Oikonomopoulos A, Ngoy S, Summer R, Fine A, Liao R. Restoration of cardiac progenitor cells after myocardial infarction by self-proliferation and selective homing of bone marrow-derived stem cells. *Circ Res*. 2005; 97:1090–1092. [PubMed: 16269652]
46. Urbanek K, Torella D, Sheikh F, De Angelis A, Nurzynska D, Silvestri F, Beltrami CA, Bussani R, Beltrami AP, Quaini F, Bolli R, Leri A, Kajstura J, Anversa P. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. *Proc Natl Acad Sci U S A*. 2005; 102:8692–8697. [PubMed: 15932947]
47. Urbanek K, Quaini F, Tasca G, Torella D, Castaldo C, Nadal-Ginard B, Leri A, Kajstura J, Quaini E, Anversa P. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. *Proc Natl Acad Sci U S A*. 2003; 100:10440–10445. [PubMed: 12928492]
48. Torella D, Ellison GM, Méndez-Ferrer S, Ibanez B, Nadal-Ginard B. Resident human cardiac stem cells: role in cardiac cellular homeostasis and potential for myocardial regeneration. *Nat Clin Pract Cardiovasc Med*. 2006; 3(Suppl 1):S8–13. [PubMed: 16501638]
49. Baur JA. Biochemical effects of SIRT1 activators. *BBA*. 2010; 1804:1626–1634. [PubMed: 19897059]
50. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins: novel therapeutic targets to treat age-associated diseases. *Nature Drug Disc*. 2008; 7:841–853.
51. Cherkas LF, Hunkin JL, Kato BS, Richards JB, Gardner JP, Surdulescu GL, Kimura M, Lu X, Spector TD, Aviv A. The association between physical activity in leisure time and leukocyte telomere length. *Arch Intern Med*. 2008; 168:154–158. [PubMed: 18227361]
52. Siu PM, Bryner RW, Martyn KJ, Always SE. Apoptotic adaptations from exercise training in skeletal and cardiac muscles. *FASEB J*. 2004; 18:1150–1152. [PubMed: 15132982]
53. Werner C, Fürster T, Widmann T, Pöss J, Roggia C, Hanhoun M, Scharhag J, Büchner N, Meyer T, Kindermann W, Haendeler J, Böhm M, Laufs U. Physical exercise prevents cellular senescence in circulating leukocytes and in the vessel wall. *Circulation*. 2009; 120:2438–2447. [PubMed: 19948976]
54. Ludlow AT, Zimmerman JB, Witkowski S, Hearn JW, Hatfield BD, Roth SM. Relationship between physical activity level, telomere length, and telomerase activity. *Med Sci Sports Exerc*. 2008; 40:1764–1771. [PubMed: 18799986]
55. Nieman DC. Immune response to heavy exertion. *J Appl Physiol*. 1997; 82:1385–1394. [PubMed: 9134882]
56. Radak Z, Taylor AW, Sasvari M, Ohno H, Horkay B, Furesz J, Gaal D, Kanel T. Telomerase activity is not altered by regular strenuous exercise in skeletal muscle or by sarcoma in liver of rats. *Redox Rep*. 2001; 6:99–103. [PubMed: 11450989]
57. Kadi F, Ponsot E. The biology of satellite cells and telomeres in human skeletal muscle: effects of aging and physical activity. *Scand J Med Sci Sports*. 2010; 20:39–48.
58. Mauro A. Satellite cell of skeletal muscle fibers. *J Biophys Biochem Cytol*. 1961; 9:493–495. [PubMed: 13768451]

59. Zammit PS, Partridge TA, Yablonka-Reuveni Z. The skeletal muscle satellite cell: the stem cell that came in from the cold. *J Histochem Cytochem*. 2006; 54:1177–1191. [PubMed: 16899758]
60. Karakelides H, Nair KS. Sarcopenia of aging and its metabolic impact. *Curr Top Dev Biol*. 2005; 68:123–148. [PubMed: 16124998]
61. Charifi N, Kadi F, Féasson L, Denis C. Effects of endurance training on satellite cell frequency in skeletal muscle of old men. *Muscle Nerve*. 2003; 28:87–92. [PubMed: 12811778]
62. Dreyer HC, Blanco CE, Sattler FR, Schroeder ET, Wiswell RA. Satellite cell numbers in young and older men 24 hours after eccentric exercise. *Muscle Nerve*. 2006; 33:242–53. [PubMed: 16315322]
63. Mackey AL, Esmarck B, Kadi F, Koskinen SO, Kongsgaard M, Sylvestersen A, Hansen JJ, Larsen G, Kjaer M. Enhanced satellite cell proliferation with resistance training in elderly men and women. *Scand J Med Sci Sports*. 2007; 17:34–42. [PubMed: 17305939]
64. Verney J, Kadi F, Charifi N, Féasson L, Saafi MA, Castells J, Piehl-Aulin K, Denis C. Effects of combined lower body endurance and upper body resistance training on the satellite cell pool in elderly subjects. *Muscle Nerve*. 2008; 38:1147–1154. [PubMed: 18671293]
65. Werner C, Hanhoun M, Widmann T, Kazakov A, Semenov A, Pöss J, Bauersachs J, Thum T, Pfreundschuh M, Müller P, Haendeler J, Böhm M, Laufs U. Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis. *J Am Coll Cardiol*. 2008; 52:470–482. [PubMed: 18672169]
66. Rogers CJ, Colbert LH, Greiner JW, Perkins SN, Hursting SD. Physical activity and cancer prevention: pathways and targets for intervention. *Sports Med*. 2008; 38:271–296. [PubMed: 18348589]
67. Cuspidi C, Lonati L, Sampieri L, Leonetti G, Zanchetti A. Physiological versus pathological hypertrophy. The athlete and the hypertensive. *Adv Exp Med Biol*. 1997; 432:145–158. [PubMed: 9433521]
68. Nass RD, Aiba T, Tomaselli GF, Akar FG. Mechanisms of disease: ion channel remodeling in the failing ventricle. *Nat Clin Pract Cardiovasc Med*. 2008; 5:196–207. [PubMed: 18317475]
69. Tomaselli GF, Marbán E. Electrophysiological remodeling in hypertrophy and heart failure. *Cardiovasc Res*. 1999; 42:270–283. [PubMed: 10533566]
70. Gwathmey JK, Slawsky MT, Perreault CL, Briggs GM, Morgan JP, Wei JY. Effect of exercise conditioning on excitation-contraction coupling in aged rats. *J Appl Physiol*. 1990; 69:1366–1371. [PubMed: 2262455]
71. Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R. Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. *Arterioscler Thromb Vasc Biol*. 2004; 24:684–690.
72. Thijssen DH, Vos JB, Verseyden C, van Zonneveld AJ, Smits P, Sweep FC, Hopman MT, de Boer HC. Haematopoietic stem cells and endothelial progenitor cells in healthy men: effect of aging and training. *Aging Cell*. 2006; 5:495–503. [PubMed: 17081158]
73. Sarto P, Balducci E, Balconi G, Fiordaliso F, Merlo L, Tuzzato G, Pappagallo GL, Frigato N, Zanolto A, Forestieri C, Azzarello G, Mazzucco A, Valenti MT, Alborino F, Noventa D, Vinante O, Pascotto P, Sartore S, Dejana E, Latini R. Effects of exercise training on endothelial progenitor cells in patients with chronic heart failure. *J Card Fail*. 2007; 13:701–708. [PubMed: 17996817]
74. Laufs U, Urhausen A, Werner N, Scharhag J, Heitz A, Kissner G, Böhm M, Kindermann W, Nickenig G. Running exercise of different duration and intensity: effect on endothelial progenitor cells in healthy subjects. *Eur J Cardiovasc Prev Rehabil*. 2005; 12:407–414. [PubMed: 16079651]
75. Luk TH, Dai YL, Siu CW, Yiu KH, Chan HT, Fong DY, Lee SW, Li SW, Tam S, Lau CP, Tse HF. Habitual physical activity is associated with endothelial function and endothelial progenitor cells in patients with stable coronary artery disease. *Eur J Cardiovasc Prev Rehabil*. 2009; 16:464–471. [PubMed: 19587603]
76. Koltai E, Szabo Z, Atalay M, Boldogh I, Naito H, Goto S, Nyakas C, Radak Z. Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats. *Mech Ageing Dev*. 2010; 131:21–28. [PubMed: 19913571]
77. Brehm M, Picard F, Ebner P, Turan G, Bölke E, Köstering M, Schüller P, Fleissner T, Ilousis D, Augusta K, Peiper M, Schannwell Ch, Strauer BE. Effects of exercise training on mobilization and

functional activity of blood-derived progenitor cells in patients with acute myocardial infarction. *Eur J Med Res.* 2009; 14:393–405. [PubMed: 19748858]

78. Schwartz, JB., Zipes, DP. Cardiovascular disease in the elderly. In: Braunwald, E. Zipes, DP., Libby, P., editors. *Heart Disease*. 8. Philadelphia: WB Saunders; 2007.
79. Gerstenblith G, Frederiksen J, Yin FC, Fortuin NJ, Lakatta EG, Weisfeldt ML. Echocardiographic assessment of a normal adult aging population. *Circulation.* 1977; 56:273–278. [PubMed: 872321]
80. Anversa P, Beghi C, Kikkawa Y, Olivetti G. Myocardial infarction in rats. Infarct size, myocyte hypertrophy, and capillary growth. *Circ Res.* 1986; 58:26–37. [PubMed: 3943155]
81. Goor D, Lillehei CW, Edwards JE. The “sigmoid septum” Variation in the contour of the left ventricular out. *Am J Roentgenol Radium Ther Nucl Med.* 1969; 107:366–376.
82. Rodeheffer RJ, Gerstenblith G, Becker LC, Fleg JL, Weisfeldt ML, Lakatta EG. Exercise cardiac output is maintained with advancing age in healthy human subjects: cardiac dilatation and increased stroke volume compensate for a diminished heart rate. *Circulation.* 1984; 69:203–213. [PubMed: 6690093]
83. Miller TR, Grossman SJ, Schectman KB, Biello DR, Ludbrook PA, Ehsani AA. Left ventricular diastolic filling and its association with age. *Am J Cardiol.* 1986; 58:531–535. [PubMed: 3751916]
84. Little WC, Zile MR, Kitzman DW, Hundley WG, O’Brien TX, Degroff RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. *J Card Fail.* 2005; 11:191–195. [PubMed: 15812746]
85. Swinne CJ, Shapiro EP, Lima SD, Fleg JL. Age-associated changes in left ventricular diastolic performance during isometric exercise in normal subjects. *Am J Cardiol.* 1992; 69:823–826. [PubMed: 1546666]
86. Galetta F, Franzoni F, Femia FR, Bartolomucci F, Carpi A, Santoro G. Left ventricular diastolic function and carotid artery wall in elderly athletes and sedentary controls. *Biomed Pharmacother.* 2004; 58:437–442. [PubMed: 15464872]
87. Kelly RP, Ting CT, Yang TM, Liu CP, Maughan WL, Chang MS, Kass DA. Effective arterial elastance as index of arterial vascular load in humans. *Circulation.* 1992; 86:513–521. [PubMed: 1638719]
88. McVeigh GE, Burns DE, Finkelstein SM, McDonald KM, Mock JE, Feske W, Carlyle PF, Flack J, Grimm R, Cohn JN. Reduced vascular compliance as a marker for essential hypertension. *Am J Hypertens.* 1991; 4:245–251. [PubMed: 2043302]
89. Rowe JW. Clinical consequences of age-related impairments in vascular compliance. *Am J Cardiol.* 1987; 60:68G–71G.
90. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. *Circulation.* 2003; 107:714–720. [PubMed: 12578874]
91. Laurent S, Katsahian S, Fassot C, Tropeano AI, Gautier I, Laloux B, Boutouyrie P. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. *Stroke.* 2003; 34:1203–1206. [PubMed: 12677025]
92. Vaitkevicius PV, Fleg JL, Engel JH, O’Connor FC, Wright JG, Lakatta LE, Yin FC, Lakatta EG. Effects of age and aerobic capacity on arterial stiffness in healthy adults. *Circulation.* 1993; 88:1456–1462. [PubMed: 8403292]
93. Lindner M, Böhle T, Beuckelmann DJ. Ca²⁺-handling in heart failure—a review focusing on Ca²⁺ sparks. *Basic Res Cardiol.* 2002; 97(Suppl 1):I79–82. [PubMed: 12479239]
94. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. *Eur Heart J.* 1996; 17:354–381. [PubMed: 8737210]
95. Bootsma M, Swenne CA, Van Bolhuis HH, Chang PC, Cats VM, Bruschke AV. Heart rate and heart rate variability as indexes of sympathovagal balance. *Am J Physiol.* 1994; 266(4 Pt 2):H1565–1571. [PubMed: 8184935]
96. Sandercock GR, Brodie DA. The use of heart rate variability measures to assess autonomic control during exercise. *Scand J Med Sci Sports.* 2006; 16:302–313. [PubMed: 16774653]
97. Pagani M, Lucini D. Autonomic dysregulation in essential hypertension: insight from heart rate and arterial pressure variability. *Auton Neurosci.* 2001; 90:76–82. [PubMed: 11485295]

98. Sevre K, Lefrandt JD, Nordby G, Os I, Mulder M, Gans RO, Rostrup M, Smit AJ. Autonomic function in hypertensive and normotensive subjects: the importance of gender. *Hypertension*. 2001; 37:1351–1356. [PubMed: 11408376]
99. Galetta F, Franzoni F, Fallahi P, Tocchini L, Graci F, Carpi A, Antonelli A, Santoro G. Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy. *Biomed Pharmacother*. 2010; 64:516–520. [PubMed: 20044234]
100. Dalla Pozza R, Bechtold S, Bonfig W, Putzker S, Kozlik-Feldmann R, Schwarz HP, Netz H. Impaired short-term blood pressure regulation and autonomic dysbalance in children with type 1 diabetes mellitus. *Diabetologia*. 2007; 50:2417–2423. [PubMed: 17898991]
101. de Farah VM, De Angelis K, Joaquim LF, Candido GO, Bernardes N, Fazan R Jr, Schaan BD, Irigoyen MC. Autonomic modulation of arterial pressure and heart rate variability in hypertensive diabetic rats. *Clinics (Sao Paulo)*. 2007; 62:477–482. [PubMed: 17823711]
102. De Angelis K, Irigoyen MC, Morris M. Diabetes and cardiovascular autonomic dysfunction: application of animal models. *Auton Neurosci*. 2009; 145:3–10. [PubMed: 19054720]
103. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. *Diabetes Care*. 2003; 26:1553–1579. [PubMed: 12716821]
104. Nasr N, Pavy-Le Traon A, Larrue V. Baroreflex sensitivity is impaired in bilateral carotid atherosclerosis. *Stroke*. 2005; 36:1891–1895. [PubMed: 16100025]
105. Munjal S, Koval T, Muhammad R, Jin Y, Demmel V, Roethig HJ, Mendes P, Unverdorben M. Heart rate variability increases with reductions in cigarette smoke exposure after 3 days. *J Cardiovasc Pharmacol Ther*. 2009; 14:192–198. [PubMed: 19592602]
106. Felber Dietrich D, Schwartz J, Schindler C, Gaspoz JM, Barthélémy JC, Tschopp JM, Roche F, von Eckardstein A, Brändli O, Leuenberger P, Gold DR, Ackermann-Liebrich U. SAPALDIA-team. Effects of passive smoking on heart rate variability, heart rate and blood pressure: an observational study. *Int J Epidemiol*. 2007; 36:834–840. [PubMed: 17440032]
107. Karakaya O, Barutcu I, Kaya D, Esen AM, Saglam M, Melek M, Onrat E, Turkmen M, Esen OB, Kaymaz C. Acute effect of cigarette smoking on heart rate variability. *Angiology*. 2007; 58:620–624. [PubMed: 18024948]
108. De Jong MJ, Randall DC. Heart rate variability analysis in the assessment of autonomic function in heart failure. *J Cardiovasc Nurs*. 2005; 20:186–195. [PubMed: 15870589]
109. Adamopoulos S, Ponikowski P, Cerquetani E, Piepoli M, Rosano G, Sleight P, Coats AJ. Circadian pattern of heart rate variability in chronic heart failure patients. Effects of physical training. *Eur Heart J*. 1995; 16:1380–1386. [PubMed: 8746907]
110. La Rovere MT Jr, Bigger JT, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. *Lancet*. 1998; 351:478–484. [PubMed: 9482439]
111. La Rovere MT, Pinna GD, Hohnloser SH, Marcus FI, Mortara A, Nohara R, Bigger JT Jr, Camm AJ, Schwartz PJ. ATRAMI Investigators. Autonomic Tone and Reflexes After Myocardial Infarction. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. *Circulation*. 2001; 103:2072–2077. [PubMed: 11319197]
112. Kleiger RE, Miller JP Jr, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *Am J Cardiol*. 1987; 59:256–262. [PubMed: 3812275]
113. Chen PS, Chen LS, Cao JM, Sharifi B, Karagueuzian HS, Fishbein MC. Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death. *Cardiovasc Res*. 2001; 50:409–416. [PubMed: 11334845]
114. Rubart M, Zipes DP. Mechanisms of sudden cardiac death. *J Clin Invest*. 2005; 115:2305–2315. [PubMed: 16138184]
115. De Ferrari GM, Salvati P, Grossoni M, Ukmars G, Vaga L, Patrono C, Schwartz PJ. Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. A study with propranolol, methacholine and oxotremorine in conscious dogs with a healed myocardial infarction. *J Am Coll Cardiol*. 1993; 22:283–290. [PubMed: 8509552]

116. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. Beta-blockers and sudden cardiac death. *Ann Intern Med.* 1995; 123:358–367. [PubMed: 7625625]
117. Du XJ, Cox HS, Dart AM, Esler MD. Sympathetic activation triggers ventricular arrhythmias in rat heart with chronic infarction and failure. *Cardiovasc Res.* 1999; 43:919–929. [PubMed: 10615419]
118. Lujan HL, Palani G, Zhang L, Dicarlo SE. Targeted Ablation of Cardiac Sympathetic Neurons reduces the susceptibility to ischemia-induced sustained ventricular tachycardia in conscious rats. *Am J Physiol Heart Circ Physiol.* 2010; 298:H1330–1339. [PubMed: 20173045]
119. Ogawa M, Zhou S, Tan AY, Fishbein MC, Lin SF, Chen LS, Chen PS. What have we learned about the contribution of autonomic nervous system to human arrhythmia? *Heart Rhythm.* 2009; 6:S8–11.
120. Akutsu Y, Kaneko K, Kodama Y, Li HL, Kawamura M, Asano T, Tanno K, Shinozuka A, Gokan T, Kobayashi Y. The significance of cardiac sympathetic nervous system abnormality in the long-term prognosis of patients with a history of ventricular tachyarrhythmia. *J Nucl Med.* 2009; 50:61–67. [PubMed: 19091900]
121. Fazio G, Novo G, Sutera L, Di Gesaro G, Fazio M, D'Angelo L, Visconti C, Vernuccio D, Pipitone S, Novo S. Sympathetic tone and ventricular tachycardia. *J Cardiovasc Med (Hagerstown).* 2008; 9:963–966. [PubMed: 18695441]
122. Piepoli MF, Capucci A. Autonomic nervous system in the genesis of arrhythmias in chronic heart failure: implication for risk stratification. *Minerva Cardioangiol.* 2007; 55:325–333. [PubMed: 17534251]
123. Carter JB, Banister EW, Blaber AP. Effect of endurance exercise on autonomic control of heart rate. *Sports Med.* 2003; 33:33–46. [PubMed: 12477376]
124. Galletta F, Franzoni F, Femia FR, Roccella N, Pentimone F, Santoro G. Lifelong physical training prevents the age-related impairment of heart rate variability and exercise capacity in elderly people. *J Sports Med Phys Fitness.* 2005; 45:217–221. [PubMed: 16355084]
125. Billman GE. Cardiac autonomic neural remodeling and susceptibility to sudden cardiac death: effect of endurance exercise training. *Am J Physiol Heart Circ Physiol.* 2009; 297:H1171–1193. [PubMed: 19684184]
126. Ino-Oka E, Sekino H, Ohtaki Y, Inooka H. Effects of daily physical activity level on the degree of sympathetic tone. *Intern Med.* 2009; 48:19–24. [PubMed: 19122352]
127. Sridhar B, Haleagrahara N, Bhat R, Kulur AB, Avabratha S, Adhikary P. Increase in the heart rate variability with deep breathing in diabetic patients after 12-month exercise training. *Tohoku J Exp Med.* 2010; 220:107–113. [PubMed: 20139661]
128. Wanner SP, Guimar Es JB, Pires W, La Guardia RB, Haibara AS, Marubayashi U, Coimbra CC, Resende N, Lima V. Physical exercise-induced cardiovascular adjustments are modulated by muscarinic cholinergic receptors within the ventromedial hypothalamic nucleus. *Physiol Res.* 2010; 59:165–175. [PubMed: 19537936]
129. Roveda F, Middlekauff HR, Rondon MU, Reis SF, Souza M, Nastari L, Barretto AC, Krieger EM, Negrão CE. The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial. *J Am Coll Cardiol.* 2003; 42:854–860. [PubMed: 12957432]
130. Bertagnolli M, Schenkel PC, Campos C, Mostarda CT, Casarini DE, Belló-Klein A, Irigoyen MC, Rigatto K. Exercise training reduces sympathetic modulation on cardiovascular system and cardiac oxidative stress in spontaneously hypertensive rats. *Am J Hypertens.* 2008; 21:1188–1193. [PubMed: 18787517]
131. Baumert M, Brechtel L, Lock J, Hermsdorf M, Wolff R, Baier V, Voss A. Heart rate variability, blood pressure variability, and baroreflex sensitivity in overtrained athletes. *Clin J Sport Med.* 2006; 16:412–417. [PubMed: 17016118]
132. De Meersman RE. Aging as a modulator of respiratory sinus arrhythmia. *J Gerontol.* 1993; 48:B74–78. [PubMed: 8473691]
133. Billman GE. A comprehensive review and analysis of 25 years of data from an *in vivo* canine model of sudden cardiac death: implications for future anti-arrhythmic drug development. *Pharmacol Therap.* 2006; 111:808–835. [PubMed: 16483666]

134. Bloomquist CG, Saltin B. Cardiovascular adaptations to physical exercise. *Ann Rev Physiol.* 1983; 45:169–189. [PubMed: 6221687]
135. Buch AN, Coote JH, Townsend JN. Morality, cardiac vagal control and physical training—what's the link? *Exp Physiol.* 2002; 87:423–435. [PubMed: 12392106]
136. Galetta F, Franzoni F, Femia FR, Roccella N, Pentimone F, Santoro G. Lifelong physical training prevents the age-related impairment of heart rate variability and exercise capacity in elderly people. *J Sports Med Phys Fitness.* 2005; 45:217–221. [PubMed: 16355084]
137. Billman GE. Aerobic exercise conditioning: a nonpharmacological antiarrhythmic intervention. *J Appl Physiol.* 2002; 92:446–454. [PubMed: 11796650]
138. Buchheit M, Millet GP, Parisy A, Pourchez S, Laursen PB, Ahmaidi S. Supramaximal training and postexercise parasympathetic reactivation in adolescents. *Med Sci Sports Exerc.* 2008; 40:362–371. [PubMed: 18202564]
139. Genovesi S, Zaccaria D, Rossi E, Valsecchi MG, Stella A, Stramba-Badiale M. Effects of exercise training on heart rate and QT interval in healthy young individuals: are there gender differences? *Europace.* 2007; 9:55–60. [PubMed: 17224424]
140. Goldsmith RL Jr, Bigger JT, Steineman RC, Fleiss JL. Comparison of 24-hour parasympathetic activity in endurance trained and untrained young men. *J Am Coll Cardiol.* 1992; 20:552–558. [PubMed: 1512332]
141. DeSchryver C, Mertens-Strythagen J. Heart tissue acetylcholine in chronically exercised rats. *Experientia.* 1975; 31:316–318. [PubMed: 1116535]
142. Sylvestre-Gervais L, Nadeau A, Nguyen MH, Tancrede G, Rousseau-Mignerol S. Effects of physical training on -adrenergic receptors in rat myocardial tissue. *Cardiovasc Res.* 1982; 16:530–535. [PubMed: 6293710]
143. Duru F, Candinas R, Dziekan G, Goebbels U, Myers J, Dubachi P. Effect of exercise training on heart rate variability in patients with new-onset left ventricular dysfunction after myocardial infarction. *Am Heart J.* 2000; 140:157–161. [PubMed: 10874279]
144. Collier SR, Kanaley JA Jr, Carhart R, Frechette V, Tobin MM, Bennett N, Luckenbaugh AN, Fernhall B. Cardiac autonomic function and baroreflex changes following 4 weeks of resistance versus aerobic training individuals with pre-hypertension. *Acta Physiol.* 2009; 195:339–348.
145. Billman GE, Kukiela M. Effect of endurance exercise training on the heart rate onset and heart rate recovery responses to submaximal exercise in animals susceptible to ventricular fibrillation. *J Applied Physiol.* 2007; 102:231–240. [PubMed: 17008437]
146. Barbier J, Rannou-Bekono F, Marchais J, Berthon PM, Delamarche P, Carre F. Effect of exercise training on 1, 2, 3, adrenergic and M2 muscarinic receptors in rat heart. *Med Sci Sports Exerc.* 2004; 36:949–954. [PubMed: 15179163]
147. Mazzeo RS, Podolin DA, Henry V. Effects of age and endurance training on adrenergic receptor characteristics in Fischer 344 rats. *Mech Age Develop.* 1995; 84:157–169.
148. MacDonnell SM, Kubo H, Crabbe DL, Renna BF, Reger PO, Mohara J, Smithwick LA, Koch WJ, Houser SR, Libonati JR. Improved myocardial-adrenergic responsiveness and signaling with exercise training in hypertension. *Circulation.* 2005; 111:3420–3428. [PubMed: 15967848]
149. Billman GE, Kukiela M. Effect of endurance exercise training on heart rate onset and heart rate recovery responses to submaximal exercise in animals susceptible to ventricular fibrillation. *J Appl Physiol.* 2007; 102:231–240. [PubMed: 17008437]
150. Mimura J, Yuasa F, Yuyama R, Kawamura A, Iwasaki M, Sugiura T, Iwasaka T. The effect of residential exercise training on baroreflex control of heart rate and sympathetic nerve activity in patients with acute myocardial infarction. *Chest.* 2005; 127:1108–1115. [PubMed: 15821182]
151. Rosenwinkel ET, Bloomfield DM, Arwady MA, Goldsmith RL. Exercise and autonomic function in health and cardiovascular disease. *Cardiol Clin.* 2001; 19:369–387. [PubMed: 11570111]
152. Westhoff TH, Franke N, Schmidt S, Vallbracht-Israng K, Zidek W, Dimeo F, van der Giet M. Beta-blockers do not impair the cardiovascular benefits of endurance training in hypertensives. *J Hum Hypertens.* 2007; 21:486–493. [PubMed: 17330056]
153. Sipido KR, Bito V, Antoons G, Volders PG, Vos MA. Na/Ca exchange and cardiac ventricular arrhythmias. *Ann N Y Acad Sci.* 2007; 1099:339–348. [PubMed: 17446474]

154. Billman GE. The antiarrhythmic and antifibrillatory effects of calcium antagonists. *J Cardiovasc Pharmacol.* 1991; 18(Suppl 10):S107–117. [PubMed: 1724998]
155. Bers DM. Cardiac excitation-contraction coupling. *Nature.* 2002; 415:198–205. [PubMed: 11805843]
156. Amin AS, Tan HL, Wilde AA. Cardiac ion channels in health and disease. *Heart Rhythm.* 2010; 7:117–126. [PubMed: 19875343]
157. Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. *Physiol Rev.* 2005; 85:1205–1253. [PubMed: 16183911]
158. Kroon PA, Iyer A, Chunduri P, Chan V, Brown L. The cardiovascular nutraceutical pharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential. *Curr Med Chem.* 2010; 17:2442–2455. [PubMed: 20491649]
159. Fleg JL, O'Connor F, Gerstenblith G, Becker LC, Clulow J, Schulman SP, Lakatta EG. Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. *J Appl Physiol.* 1995; 78:890–900. [PubMed: 7775334]
160. Virmani R, Avolio AP, Mergner WJ, Robinowitz M, Herderick EE, Cornhill JF, Guo SY, Liu TH, Ou DY, O'Rourke M. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. *Am J Pathol.* 1991; 139:1119–1129. [PubMed: 1951629]
161. Challah M, Nadaud S, Philippe M, Battle T, Soubrier F, Corman B, Michel JB. Circulating and cellular markers of endothelial dysfunction with aging in rats. *Am J Physiol.* 1997; 273:H1941–1948. [PubMed: 9362264]
162. Seals DR. Habitual exercise and the age-associated decline in large artery compliance. *Exerc Sport Sci Rev.* 2003; 31:68–72. [PubMed: 12715969]
163. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I. Expert consensus document on arterial stiffness: methodological issues and clinical applications. *Eur Heart J.* 2006; 27:2588–2605. [PubMed: 17000623]
164. Vlachopoulos C, Aznaouridis K, Stefanadis C. Clinical appraisal of arterial stiffness: the Argonauts in front of the Golden Fleece. *Heart.* 2006; 92:1544–1550. [PubMed: 16339817]
165. Agabiti-Rosei E, Mancia G, O'Rourke MF, Roman MJ, Safar ME, Smulyan H, Wang JG, Wilkinson IB, Williams B, Vlachopoulos C. Central blood pressure measurements and antihypertensive therapy: a consensus document. *Hypertension.* 2007; 50:154–160. [PubMed: 17562972]
166. Vaitkevicius PV, Fleg JL, Engel JH, O'Connor FC, Wright JG, Lakatta LE, Yin FC, Lakatta EG. Effects of age and aerobic capacity on arterial stiffness in healthy adults. *Circulation.* 1993; 88:1456–1462. [PubMed: 8403292]
167. Tanaka H, Dinunno FA, Monahan KD, Clevenger CM, Desouza CA, Seals DR. Aging, habitual exercise, and dynamic arterial compliance. *Circulation.* 2000; 102:1270–1275. [PubMed: 10982542]
168. Franzoni F, Galetta F, Cupisti A, Femia FR, Pentimone F, Santoro G. Ultrasonic backscatter of the carotid wall in young and older athletes. *J Int Med.* 2004; 255:52–58.
169. Moreau KL, Gavin KM, Plum AE, Seals DR. Ascorbic acid selectively improves large elastic artery compliance in postmenopausal women. *Hypertension.* 2005; 45:1107–1112. [PubMed: 15867135]
170. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, Sudano I, Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. *Circulation.* 1995; 91:1981–1987. [PubMed: 7895356]
171. Yu BP, Chung HY. Oxidative stress and vascular aging. *Diabetes Res Clin Pract.* 2001; 54(Suppl 2):S73–80. [PubMed: 11733112]
172. Brandes RP, Fleming I, Busse RR. Endothelial aging. *Cardiovasc Res.* 2005; 66:286–294. [PubMed: 15820197]
173. Csizsar A, Ungvari Z, Edwards JG, Kaminski P, Wolin MS, Koller A, Kaley G. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. *Circ Res.* 2002; 90:1159–1166. [PubMed: 12065318]

174. DeSouza CA, Shapiro LF, Clevenger CM, Dinunno FA, Monahan KD, Tanaka H, Seals DR. Regular aerobic exercise prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men. *Circulation*. 2000; 102:1351–1357. [PubMed: 10993851]
175. Eskurza I, Monahan KD, Robinson JA, Seals DR. Effect of acute and chronic ascorbic acid on flow-mediated dilatation with sedentary and physically active human ageing. *J Physiol*. 2004; 556:315–324. [PubMed: 14754992]
176. Taddei S, Galetta F, Virdis A, Ghiadoni L, Salvetti G, Franzoni F, Giusti C, Salvetti A. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. *Circulation*. 2000; 101:2896–2901. [PubMed: 10869260]
177. Lavrencic A, Salobir BG, Keber I. Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome. *Arterioscler Thromb Vasc Biol*. 2000; 20:551–555. [PubMed: 10671187]
178. Spier SA, Delp MD, Meininger CJ, Donato AJ, Ramsey MW, Muller-Delp JM. Effects of ageing and exercise training on endothelium-dependent vasodilatation and structure of rat skeletal muscle arterioles. *J Physiol*. 2004; 556:947–958. [PubMed: 15004211]
179. Hambrecht R, Adams V, Erbs S, Linke A, Krankel N, Shu Y, Baither Y, Gielen S, Thiele H, Gummert JF, Mohr FW, Schuler G. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. *Circulation*. 2003; 107:3152–3158. [PubMed: 12810615]
180. Franzoni F, Ghiadoni L, Galetta F, Plantinga Y, Lubrano V, Huang Y, Salvetti G, Regoli F, Taddei S, Santoro G, Salvetti A. Physical activity, plasma antioxidant capacity, and endothelium-dependent vasodilation in young and older men. *Am J Hypertens*. 2005; 18:510–516. [PubMed: 15831361]
181. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. *Am J Epidemiol*. 1990; 132:612–628. [PubMed: 2144946]
182. Sesso HD Jr, Paffenbarger RS, Lee IM. Physical activity and coronary heart disease in men: The Harvard Alumni Health Study. *Circulation*. 2000; 102:975–980. [PubMed: 10961960]
183. Lee IM, Sesso HD Jr, Paffenbarger RS. Physical activity and coronary heart disease risk in men: does the duration of exercise episodes predict risk? *Circulation*. 2000; 102:981–986. [PubMed: 10961961]
184. Ekelund LG, Haskell WL, Johnson JL, Whaley FS, Criqui MH, Sheps DS. Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men. The Lipid Research Clinics Mortality Follow-up Study. *N Engl J Med*. 1988; 319:1379–1384. [PubMed: 3185648]
185. Kim JR, Oberman A, Fletcher GF, Lee JY. Effect of exercise intensity and frequency on lipid levels in men with coronary heart disease: Training Level Comparison Trial. *Am J Cardiol*. 2001; 87:942–946. [PubMed: 11305982]
186. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, Sugawara A, Totsuka K, Shimano H, Ohashi Y, Yamada N, Sone H. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. *JAMA*. 2009; 301:2024–2035. [PubMed: 19454641]
187. Taddei S, Galetta F, Virdis A, Ghiadoni L, Salvetti G, Franzoni F, Giusti C, Salvetti A. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. *Circulation*. 2000; 101:2896–2901. [PubMed: 10869260]
188. Galetta F, Franzoni F, Virdis A, Ghiadoni L, Taddei S, Salvetti A, Santoro G. Endothelium-dependent vasodilation and carotid artery wall remodeling in athletes and sedentary subjects. *Atherosclerosis*. 2006; 186:184–192. [PubMed: 16102774]
189. American Geriatrics Society, British Geriatrics Society, American Academy of Orthopaedic Surgeons Panel on Falls Prevention. Guideline for the prevention of falls in older persons. *J Am Geriatr Soc*. 2001; 49:664–672. [PubMed: 11380764]
190. Kesaniemi Y Jr, Danforth E, Jensen M, Kopelman P, Lefebvre P, Reeder B. Dose-response issues concerning physical activity and health: an evidence-based symposium. *Med Sci Sports Exerc*. 2001; 33(6 Suppl):S351–S358. [PubMed: 11427759]
191. Nelson M, Layne J, Bernstein M, Nuernberger A, Castaneda C, Kaliton D, Hausdorff J, Judgde JO, Buchner DM, Roubenoff R, Fiatarone Singh MA. The effects of multidimensional home-

based exercise on functional performance in elderly people. *J Gerontol A Biol Sci Med Sci*. 2004; 59A:154–160.

192. Thompson P, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, Blair SN, Costa F, Franklin B, Fletcher GF, Gordon NF, Pate RR, Rodriguez BL, Yancey AK, Wenger NK. American Heart Association Council on Clinical Cardiology Subcommittee on Exercise, Rehabilitation, and Prevention; American Heart Association Council on Nutrition, Physical Activity and Metabolism Subcommittee on Physical Activity. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). *Circulation*. 2003; 107:3109–3116. [PubMed: 12821592]
193. McDermott H, Liu K, Ferrucci L, Criqui MH, Greenland P, Guralnik JM, Tian L, Schneider JR, Pearce WH, Tan J, Martin GJ. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. *Ann Intern Med*. 2006; 144:10–20. [PubMed: 16389250]
194. Sigal R, Kenny G, Wasserman D, Castaneda-Sceppa C. Physical activity/exercise and type 2 diabetes. *Diabetes Care*. 2004; 27:2518–2539. [PubMed: 15451933]
195. Preventive Services Task Force US. Screening for obesity in adults: recommendations and rationale. *Ann Intern Med*. 2003; 139:930–932. [PubMed: 14644896]
196. Going S, Lohman T, Houtkooper L, Metcalfe L, Flint-Wagner H, Blew R, Stanford V, Cussler E, Martin J, Teixeira P, Harris M, Milliken L, Figueroa-Galvez A, Weber J. Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy. *Osteoporos Int*. 2003; 14:637–643.
197. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. American College of Rheumatology Recommendations for the medical management of osteoarthritis of the hip knee 2000 update. *Arthritis Rheum*. 2000; 43:1905–1915. [PubMed: 11014340]
198. Stewart K, Hiatt W, Regensteiner J, Hirsch A. Exercise training for claudication. *N Engl J Med*. 2002; 347:1941–1951. [PubMed: 12477945]
199. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. GOLD Scientific Committee. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med*. 2001; 163:1256–1276. [PubMed: 11316667]
200. Brosse A, Sheets E, Lett H, Blumenthal J. Exercise and the treatment of clinical depression in adults: recent findings and future directions. *Sports Med*. 2002; 32:741–760. [PubMed: 12238939]
201. Doody R, Stevens J, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2001; 56:1154–1166. [PubMed: 11342679]
202. Panel on Persistent Pain in Older Persons AGS. The management of persistent pain in older persons. *J Am Geriatr Soc*. 2002; 50(6 Suppl):S205–S224. [PubMed: 12067390]
203. Abbott RD, White LR, Ross GW, Masaki KH, Curb JD, Petrovitch H. Walking and dementia in physically capable elderly men. *JAMA*. 2004; 292:1447–1453. [PubMed: 15383515]
204. Penninx BW, Messier SP, Rejeski WJ, Williamson JD, DiBari M, Cavazzini C, Applegate WB, Pahor M. Physical exercise and the prevention of disability in activities of daily living in older persons with osteoarthritis. *Arch Intern Med*. 2001; 161:2309–2316. [PubMed: 11606146]
205. Singh N, Clements K, Fiatarone M. A randomized controller trial of the effect of exercise on sleep. *Sleep*. 1997; 20:95–101. [PubMed: 9143068]
206. Paffenbarger RS Jr, Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. *N Engl J Med*. 1993; 328:538–545. [PubMed: 8426621]
207. Paffenbarger RS Jr, Hyde RT, Wing AL, Hsieh CC. Physically activity, all-cause mortality, and longevity of college alumni. *N Engl J Med*. 1986; 314:605–613. [PubMed: 3945246]

208. Kokkinos P, Sheriff H, Kheirbek R. Physical inactivity and mortality risk. *Cardiol Res Pract*. 2011; 2011:924–945.
209. Lee IM, Skerrett PJ. Physical activity and all-cause mortality: what is the dose-response relation? *Med Sci Sports Exerc*. 2001; 33(6 Suppl):S459–471. [PubMed: 11427772]
210. Brunner D, Manelis G, Modan M, Levin S. Physical activity at work and the incidence of myocardial infarction, angina pectoris and death due to ischemic heart disease. An epidemiological study in Israeli collective settlements (Kibbutzim). *J Chronic Dis*. 1974; 27:217–233. [PubMed: 4843254]
211. Kohl HW 3rd. Physical activity and cardiovascular disease: evidence for a dose response. *Med Sci Sports Exerc*. 2001; 33(6 Suppl):S472–483. discussion S493–4. [PubMed: 11427773]
212. Kujal UM, Kaprio J, Sarna S, Koskenvuo M. Relationship of leisure-time physical activity and mortality: the Finnish Twin Cohort. *JAMA*. 1998; 279:440–444. [PubMed: 9466636]
213. Lakka TA, Venäläinen JM, Rauramaa R, Salonen R, Tuomilehto J, Salonen JT. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction in men. *N Engl J Med*. 1994; 330:1549–1554. [PubMed: 8177243]
214. Tanasescu M, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Exercise type and intensity in relation to coronary heart disease in men. *JAMA*. 2002; 288:1994–2000. [PubMed: 12387651]

Figure 1.
Describes the protective role of SODs in cardiovascular diseases.

Table 1

Summary of characteristics of Sirtuins or Class III Deacetylases (Modified from Haigis, 2010) Sirtuins involved in cardiac protections (1,3,4 and 7) are underlined

Sirtuin	Chromosome	Subcellular Location	Targets/Interaction	Function/Pathology	Transgenic mice: KO or SIRT overexpressing (+/+)
<u>SIRT1</u>	10q21.3	Nucleus/cytosol	histones H1/H4, FOXO, NFKB, PGC1 α , Ku70, p53, AROS, WRN, PPARY, LXR, E2F, E2F1, NCOR, MyoD, ecc.	Oxidative stress resistance Metabolism, ageing, mitochondriogenesis, inflammatory response, genomic stability, etc.	KO : developmental defects or lethal SIRT1 ^{+/+} ; anti-ageing, anti stress, cardioprotective, neuroprotective
<u>SIRT2</u>	19q13.2	Cytosol	Tubulin, cytoskeleton, H4, FOXO, 14-3-3 protein	Cell cycle, apoptosis	KO : normal development SIRT2 ^{+/+} ; neuroprotective
<u>SIRT3</u>	11p15.5	Mitochondria Nucleus (Cytoplasm)	AceCS2, GDH, Cytochrome complex I, Ku70, FOXO3a, PGC1 α , histones H3/H4	Thermogenesis, Energy metabolism, ATP production Scavenging ROS, antiapoptotic (Ku70/Bax interaction)	KO : normal development, hyperacetylated mt-proteins SIRT3 ^{+/+} ; protects from agonist induced hypertrophy
<u>SIRT4</u>	12q24.31	Mitochondria	GDH, IDE, ANT2, ANT3	Energy metabolism, insulin secretion and diabetes	KO : normal development SIRT4 ^{+/+} ;
<u>SIRT5</u>	6p23	Mitochondria	CPS1	Urea cycle, neuropathology	KO : normal development SIRT5 ^{+/+} ;
<u>SIRT6</u>	19p13.3	Nucleus	Histone H3, NFKB	BER or base excision repair, metabolism, genomic stability, glucose homeostasis	KO : premature ageing SIRT6 ^{+/+} ;
<u>SIRT7</u>	17q25.3	Nucleolus and condensed chromatin	RNA polymerase I, p53	Recombinant DNA transcription, maintenance of tissues, myocardium repair	KO : smaller size, short lifespan, heart defects, hypertrophy and inflammatory cardiomyopathy SIRT7 ^{+/+} ;

AceCS2 : Acetyl-CoA-Synthetase, ANT : Adenine Nucleotide Translocator, AROS : Active Regulator of SIRT1, CPS1 : Carbamoyl phosphate synthetase 1, E2F, E2F1 : transcription factors, FOXO : Forkhead box, subgroup O, GDH : glutamate dehydrogenase, IDE : Insulin degrading enzyme, Ku70 : deubiquitinating protein for Bax and a number of other substrates, IDE : Insulin degrading enzyme, LXR : Liver X receptor, AceCS2 : Acetyl-CoA-synthase 2, MyoD : Muscle Transcription Factor (development and maintenance), NCOR : Nuclear Receptor Corepressor, NFKB : Nuclear Factor κ in B (lymphocyte), PGC1 α : Peroxisome proliferator activated receptor gamma coactivator 1 alpha, PPARY : peroxisome proliferator activated receptor gamma, p53 : protein 53, an oncosuppressor protein, SIRT : Silencing Information Regulator Two or Sir-2, WRN : Werner syndrome gene or Werner progeria, an enzyme of DNA repair mechanism, 14-3-3 protein : adaptor protein for phosphorylated serine in a number of pathways, including Akt

Table 2

Principal age related pathophysiologic characteristics which are positively affected by physical activity as well as the principal tests for each characteristic

General mechanism	Laboratory and/or instrumental test	Clinical correlate
Oxidative stress	TOSC Telomere length MnSOD Gpx MDA	Impaired contractility Heart failure
Loss of cardiac stem cell, number of pacemaker and impulse transmitting cells	ECG	Impaired lesion repair Ventricular tachyarrhythmias Bradiarrhythmias
Reduced efficiency of the intracellular Ca ²⁺ cycle	Echocardiography	Diastolic dysfunction Systolic dysfunction
Myocardium remodelling	Echocardiography	LV and LA change: thickness, size End-diastolic diameter
Vascular remodelling	Augmentation index Pulse wave velocity IMT Integrated blackscatter analysis	Arterial hypertension Arterial stiffness Arterial wall thickness Echoreflexivity
Autonomic nervous system	ECG Heart rate variability	Sympatho-vagal imbalance

TOSC= total oxyradical scavenging capacity; MnSOD= manganese superoxide dismutase; Gpx= glutathione peroxidase; MDA= malondyaldehyde; LV= left ventricle; LA= left atrium; IMT= intima-media thickness

Table 3

Principal clinical studies on the inverse relationship between physical activity and mortality or heart attack risk.

Physical activity intensity or type	Mortality risk	Heart attack risk	Reference, n
< 2000 Kcal/week vs 2000Kcal/week		60% higher	207
2000 Kcal/week vs < 2000Kcal/week	25–33% lower		207
1000 to 2000 Kcal/week vs < 500Kcal/week	30–40% lower		207
> 3500Kcal/week vs 1000 to 2000 Kcal/week	30–40% higher		207
Active vs sedentary job		2–3 times higher	210
30 min walk 6 times per month vs twins with no leisure time activity	44% lower		212